Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
% D! N5 j, V" y5 ~0 g- |7 E. T2 Z; X6 E( r/ Q8 M9 Q0 Q; m
, E8 W3 M1 @+ h2 m$ t8 ~& hSub-category:
" V: U9 z# u7 D2 s' @' \, u6 gMolecular Targets
# ] F! b& s! B, z9 ]) M$ T1 V9 e3 T$ g( `/ Z
( J* p! q: c0 |2 I0 e" o6 |3 mCategory:2 }- {# I, }& H7 o6 Y. l4 ?
Tumor Biology
4 z* M$ }: M8 o" Z" y7 t& B6 A8 }4 F5 V- a4 {% E' L3 L% o* t
% ~9 ~6 \0 |1 l$ {) L' G, a+ K: m* KMeeting:& z+ g# i* t# t+ o9 E! C
2011 ASCO Annual Meeting $ i0 c' @+ h* ?$ m$ S7 }6 e
" `+ Y& \ V3 S9 e' o* E$ A- ^
. a2 U6 K4 }3 RSession Type and Session Title:; Y7 a2 I# D) C0 k
Poster Discussion Session, Tumor Biology 3 f- z$ a6 O" O* O K
, _7 v/ o& S- ^' Q+ t
/ g( p4 L, A" fAbstract No:
* @9 H) G, v8 u10517 " v* I( Z T& a2 Z
- X" G# e1 w& ^4 J5 v
) R) ~* Z9 A) v; U1 [# c3 [9 s# }Citation:1 j/ Z Y$ W: w7 C0 M
J Clin Oncol 29: 2011 (suppl; abstr 10517)
* Q& F' g5 W0 H: m0 @" _ G( ?; X# s; U5 m+ t" S! P5 n( j
3 h" [# X0 ^+ d; Z/ rAuthor(s):
8 \" u4 U- X" V' E% j$ jJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ C* m7 Z0 V% |) C- G N* O F& V4 N9 D f5 j1 Y4 `. b
4 o" Q4 V& l) I
- g5 H# ^8 L; [3 |+ n# m! Y6 iAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
! I0 e& c3 c2 H( Z/ T
4 O! m/ w3 ?7 T0 X5 E8 n& bAbstract Disclosures& s E0 b5 J! B1 s$ v2 U
; A1 }. g& G( m; mAbstract:
7 O: | _1 z. t% u9 i) [0 |$ Q3 Q: p1 g+ }+ B0 r1 D9 ]. C: ?* `
K0 W$ R0 \6 q, K5 V$ B; n
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 _: E7 v/ D( D# f9 r; N9 @( V+ H9 U# n" y5 p0 ]3 Z7 y- e
, {, J8 G5 [! i% m0 V, x' s5 L3 I& @
|
* q g# o$ L# U Y: V8 U
显身卡
